Related by context. All words. (Click for frequent words.) 70 IMA# 70 Xanafide 69 epothilone 69 receptor tyrosine kinase inhibitor 69 PDE4 inhibitor 69 mertansine 68 Multimeric 68 metaglidasen 68 liposomal formulation 68 vidofludimus 67 Neuvenge 67 XmAb# 67 Zolinza 67 Aflibercept 67 Factor VIIa 67 SERMs 67 ixabepilone 67 Amrubicin 67 BRIM2 67 Hsp# Inhibitor 67 CCR5 inhibitor 67 proteasome inhibitor 67 Pertuzumab 67 Safinamide 67 oral prodrug 67 trabectedin 67 JAK inhibitor 67 DermaVir Patch 67 TG# [001] 67 HuMax EGFr 67 phase IIb clinical 67 MAGE A3 ASCI 66 sodium glucose cotransporter 66 UPLYSO 66 MVA BN R 66 pan HDAC inhibitor 66 CYC# 66 volociximab 66 EndoTAG 66 Aplidin 66 humanized antibody 66 immunotherapeutic agent 66 Sym# 66 generation purine nucleoside 66 orally administered inhibitor 66 Tarvacin 66 GRASPA ® 66 PN# [001] 66 ganetespib 66 IMC A# 66 AEG# 66 RhuDex ® 66 investigational humanized monoclonal antibody 66 forodesine 66 mTOR inhibitor 66 Archexin 66 vascular disrupting agent 66 seliciclib CYC# 66 Daclizumab 66 HuMax CD4 66 Onconase 65 BRAF inhibitor 65 Dapagliflozin 65 BCR ABL inhibitors 65 fosbretabulin 65 Temsirolimus 65 orally bioavailable 65 Cloretazine ® 65 Tesetaxel 65 XYOTAX TM 65 selective kinase inhibitor 65 denileukin diftitox 65 solithromycin 65 SNT MC# 65 BAY #-# 65 Akt inhibitor 65 humanized monoclonal antibody 65 Dalbavancin 65 alvespimycin 65 phase IIb trial 65 nucleoside analog 65 ASA# 65 SAR# [004] 65 Traficet EN 65 EGFr 65 reslizumab 65 somatostatin analogue 65 Blinatumomab 65 Phase #b/#a clinical 65 PSMA ADC 65 Civacir 65 APEX PD 65 PROSTVAC TM 65 ATL# [002] 65 nitric oxide donating prostaglandin 65 Phase Ib clinical 65 angiogenesis inhibitor 65 Tyrima 65 immunotherapeutic vaccine 65 Phase Ib study 65 EndoTAG TM -1 65 Lenalidomide 65 BiTE 65 MEK inhibitors 65 evaluating tivozanib 65 TLR9 agonist 64 cediranib 64 selectively binds 64 INT# [002] 64 ADP receptor antagonist 64 Silodosin 64 Maraviroc 64 metastatic hormone refractory 64 ZD# [001] 64 Pazopanib 64 DB# [003] 64 YONDELIS 64 Voreloxin 64 radiation sensitizer 64 Pralatrexate 64 Azedra 64 Intravenous CP 64 HGS# 64 TH# [003] 64 VivaGel TM 64 CCR5 antagonist 64 vemurafenib 64 BrachySil 64 MEK inhibitor 64 ELACYT 64 cathepsin K inhibitor 64 Phase Ib II 64 Carfilzomib 64 PrevOnco 64 TAFA# 64 selective modulator 64 CDK inhibitor 64 ceftazidime 64 ocular formulation 64 Elagolix 64 Phase 1a clinical 64 elotuzumab 64 chimeric monoclonal antibody 64 Pimavanserin 64 Panzem R NCD 64 Aliskiren 64 antibody MAb 64 CBLC# 64 TMC# [002] 64 MGd 64 docetaxel Taxotere R 64 NEUGENE 64 ospemifene 64 erlotinib Tarceva ® 64 Ixabepilone 64 ARX# [001] 64 OncoVEX 64 antisense drug 64 MKC# MKC# PP 64 neratinib 64 OvaRex ® MAb 64 Loramyc R 64 huC# DM4 64 OncoVEX GM CSF 64 Annamycin 64 nucleoside reverse transcriptase inhibitor 64 Dasatinib 64 immunomodulatory therapy 64 ChronVac C ® 64 CTA# 64 sunitinib malate 64 nucleoside analogue 64 novel VDA molecule 64 LB# [003] 64 phase IIb 64 CG# [003] 64 Aurora kinase 64 TRC# 64 PRT# 64 Vidaza azacitidine 64 DU #b 64 histone deacetylase HDAC inhibitor 64 Denufosol 64 Allovectin 7 64 CEQ# 63 Sapacitabine 63 Teysuno 63 Tocilizumab 63 Ceflatonin 63 Clevudine 63 TBC# 63 Insegia 63 Cloretazine VNP#M 63 phase IIa 63 Gefitinib 63 DACH platinum 63 oral ridaforolimus 63 Pemetrexed 63 registrational trial 63 dose escalation Phase 63 Velcade bortezomib 63 Glufosfamide 63 Vicriviroc 63 AQ4N 63 induced macular edema 63 murine monoclonal antibody 63 Erbitux cetuximab 63 IgG1 antibody 63 targeting CD# 63 PEGylated interferon 63 novel histone deacetylase 63 Vitaxin 63 anticancer compound 63 pharmacologically active isomer 63 virosome 63 pertuzumab 63 PEG IFN 63 ENMD # 63 sorafenib Nexavar 63 YONDELIS R 63 Maribavir 63 regorafenib 63 Symadex 63 PANVAC VF 63 phase Ib 63 protein tyrosine phosphatase 1B 63 VEGF inhibitor 63 Nexavar sorafenib 63 JVRS 63 Elvitegravir 63 HCD# [002] 63 imatinib Gleevec ® 63 EOquin TM 63 NXL# 63 Aurora kinase inhibitor 63 Reverset 63 Erlotinib 63 androgen receptor antagonist 63 Guanilib 63 riociguat 63 docetaxel Taxotere ® 63 nucleotide analogue 63 HQK 63 CTAP# Capsules 63 NM# [003] 63 axitinib 63 erlotinib Tarceva 63 polymerase inhibitor 63 Bicifadine 63 immatics 63 Fodosine 63 Curaxin 63 JAK inhibitors 63 LymphoStat B belimumab 63 GRNVAC1 63 Abiraterone 63 humanized monoclonal 63 oral antiviral 63 modulator SERM 63 potent antiproliferative 63 OMP #M# 63 drug conjugate 63 targeted radiotherapeutic 63 TriRima 63 Alfacell proprietary ribonuclease 63 intradermal injection 63 Tarceva TM 63 Epratuzumab 63 VNP#M 63 Methylnaltrexone 63 HuLuc# 63 Irinotecan 63 MDV# 63 Urocidin 63 canakinumab 63 phosphatidylserine PS targeting 63 anti angiogenic agent 63 BMS # 63 Anticalin ® 63 Deforolimus 63 selective inhibitor 63 VitiGam 63 R roscovitine 63 PD LID 63 Phase #b/#a 63 multicenter Phase II 63 ASTEROID 63 LHRH antagonist 63 OXi# 63 favorable pharmacokinetic profile 63 BrachySil TM 63 Liposomal 63 HuMax CD# 63 oncolytic 63 IMC #B 63 Aurora Kinase 63 Vicinium TM 63 Oral NKTR 63 obatoclax 63 DCVax R 63 myelofibrosis polycythemia vera 62 Clofarabine 62 eribulin mesylate 62 Alvesco R 62 Anticalins R 62 ZOLINZA 62 teriflunomide 62 CCX# 62 developing TB4 62 PNP inhibitor 62 HuMax TAC 62 TG# [003] 62 HIV integrase inhibitor 62 novel oral anticoagulant 62 Cimzia ® certolizumab pegol 62 Angiolix 62 cilengitide 62 Nexavar ® 62 Achieves Primary Endpoint 62 Leukine ® 62 monoclonal antibody mAb 62 INCB# [001] 62 selective antagonist 62 Apaziquone 62 tarenflurbil 62 initiated Phase Ib 62 Meets Primary Endpoint 62 Talabostat 62 Azilect ® 62 Transdrug ® nanoparticle 62 enzastaurin 62 IgG1 62 HCV protease inhibitor 62 MF# [002] 62 corticosteroid dexamethasone 62 atacicept 62 vinca alkaloid 62 PKC# 62 EGFR TKIs 62 Panzem R 62 cholesteryl ester transfer 62 Saxagliptin 62 anti CD# antibodies 62 Nanobody 62 Golimumab 62 luteinizing hormone releasing 62 PEGylated Fab fragment 62 tyrosine kinase inhibitor 62 Scancell 62 TroVax ® 62 fluoroquinolone antibiotic 62 LHRH 62 Olaparib 62 Cetrorelix 62 Personalized Immunotherapy 62 HDAC Inhibitor 62 Tamibarotene 62 selective androgen receptor modulator 62 Allovectin 7 ® 62 ZK EPO 62 bendamustine 62 signal transduction inhibitor 62 Bortezomib 62 Thiovir 62 Afatinib 62 renin inhibitor 62 BRAF V#E mutation 62 MAb 62 HGS ETR2 62 SPRYCEL ® 62 Neulasta ® 62 HyperAcute 62 Bavituximab 62 Tarvacin TM 62 neuraminidase inhibitor 62 NRTI resistance 62 TLR agonists 62 Anticalin R 62 Phase Ib IIa 62 gemcitabine Gemzar 62 OvaRex R 62 SCH # 62 XL# XL# XL# 62 DEB# 62 ADVANCE PD 62 sargramostim 62 TRO# 62 Removab 62 aleglitazar 62 Fludara ® 62 vascular disrupting agents 62 phase IIa clinical 62 Initiates Clinical 62 Phase IIa trials 62 Cloretazine 62 Xelox 62 Orazol 62 PSN# [002] 62 pegylated interferons 62 anti CD# monoclonal 62 Degarelix 62 RH1 62 dasatinib Sprycel 62 EP #R 62 entinostat 62 Protelos 62 Alocrest 62 chemotherapeutic drug 62 PRTX 62 Immunotherapeutic 62 Ceftaroline 62 Resten NG 62 fluoropyrimidine 62 NO# [002] 62 MVA BN 62 trastuzumab DM1 T DM1 62 targeted antifolate 62 lumiliximab 62 OvaRex MAb 62 chemically modified siRNA 62 vinorelbine tartrate 62 Abacavir 62 Lixivaptan 62 GVAX ® 62 CA9 SCAN 62 AZILECT ® 62 Vandetanib 62 Delafloxacin 62 Gleevec imatinib mesylate 62 randomized controlled Phase 62 TAT# 62 Interferon beta 62 topoisomerase II inhibitor 62 rNAPc2 62 thalidomide Thalomid 62 ChronVac C R 62 PEG SN# 62 non nucleoside inhibitor 62 HER2 antibody 62 Interferon alfa 62 Japanese Encephalitis vaccine 62 G#DT 62 rxRNA 62 Tesmilifene 62 CD# monoclonal antibody 62 MYDICAR ® 62 Pafuramidine 62 thymalfasin 62 isotype 62 delipidation 62 small molecule activators 62 Ganciclovir 62 Initiate Phase 62 tranilast 62 Trastuzumab 62 synthetic peptide 62 gefitinib Iressa 62 trivalent influenza vaccine 62 CCR9 antagonist 62 Taxotere docetaxel 62 BAL# [001] 62 Nilotinib 62 Vilazodone 62 epigenetic therapies 62 boosted protease inhibitor 62 MT#/MEDI-# 62 REMUNE R 62 Pitavastatin 62 AKT inhibitor 61 TPI ASM8 61 SCCHN 61 ALK inhibitors 61 SIR Spheres 61 Raptiva ® 61 Xeloda capecitabine 61 Shigamabs ® 61 PEGylated 61 tanespimycin 61 ONCONASE R 61 platinum chemotherapeutic 61 Pivotal Phase III 61 Gleevec resistant 61 KNS # 61 Imprime PGG 61 Aviptadil 61 depsipeptide 61 olaparib 61 PI3K/Akt pathway inhibitor 61 Randomized Phase 61 Apoptone 61 Dabigatran etexilate 61 gemcitabine Gemzar ® 61 ORENCIA R 61 Clolar ® 61 PI3K inhibitors 61 paclitaxel Taxol 61 APTIVUS 61 tolevamer 61 Vimpat R 61 Mipomersen 61 T DM1 61 multitargeted 61 somatostatin analog 61 ASONEP 61 Pivotal Trial 61 Avanafil 61 ORENCIA ® 61 ara C 61 Vectibix panitumumab 61 potent cytotoxic 61 MNTX 61 BZL# 61 peptide antigens 61 Seliciclib 61 TASQ 61 TLK# 61 SCIB1 61 Phase IIIb clinical 61 EGFR TKI 61 thrombopoietin 61 Epidermal Growth Factor Receptor 61 pegylated 61 ketolide antibiotic 61 RP# [002] 61 TLR8 agonist 61 BAL# [002] 61 torezolid 61 therapeutic monoclonal antibody 61 Moxifloxacin 61 HDACi 61 Tasimelteon 61 IRX 2 61 Telatinib 61 confirmatory Phase 61 UVIDEM 61 investigational integrase inhibitor 61 Radezolid 61 generation nucleoside analog 61 GW# [003] 61 XmAb 61 integrase inhibitor 61 Janus Kinase 61 Anavex #-# 61 acyclovir Lauriad R 61 BRIM3 61 tubulin inhibitor 61 PrevOnco ™ 61 velafermin 61 CG# [001] 61 Ophena TM 61 EOquin 61 chemopreventive agent 61 Daptomycin 61 MKC# MT 61 NP2 61 cMET 61 Tezampanel 61 Fc fusion protein 61 Bezielle 61 IPL# 61 L BLP# 61 Quinamed 61 Phase IIb Trial 61 NPM1 61 EP# [003] 61 Yondelis ® 61 Ixempra 61 androgen independent 61 CLORETAZINE TM VNP#M 61 GSK '# 61 afamelanotide 61 JAK2 inhibitor 61 NADiA 61 TASKi3 61 decitabine 61 aripiprazole Abilify 61 Litx 61 LHRH receptor positive 61 Trastuzumab DM1 61 diagnostic biomarker 61 NPC 1C 61 Telbivudine 61 GAMMAGARD 61 Protelos R 61 Lubiprostone 61 radiotherapeutic 61 IAP inhibitor 61 relapsing remitting MS RRMS 61 Inactivated 61 PARP inhibitor 61 pradefovir 61 photoprotective drug 61 Bevacizumab 61 relapsed MM 61 inhibitor RG# 61 eniluracil 61 virus HCV protease inhibitor 61 Diovan HCT 61 CYT# potent vascular disrupting 61 castrate resistant prostate cancer 61 TEMODAL 61 IAP inhibitors 61 cetuximab Erbitux 61 Olmesartan 61 deforolimus 61 interferon IFN 61 apricitabine 61 GALNS 61 JAK3 inhibitor 61 HCV protease inhibitors 61 recombinant hepatitis B 61 potent anticancer 61 Anticalins ® 61 Kahalalide F 61 macrolide antibiotics 61 microtubule inhibitor 61 RAV# 61 DermaVir 61 Pradefovir 61 Squalamine 61 acyclovir Lauriad ® 61 bexarotene 61 tumor vascular disrupting 61 non nucleoside 61 Perifosine 61 metastatic castrate resistant 61 Bruton tyrosine kinase Btk 61 Vidaza R 61 adenoviral vectors 61 antisense oligonucleotide 61 Phase IIb clinical trials 61 farletuzumab 61 Genasense ® 61 HepDirect prodrug 61 Onalta ™ 61 vorinostat 61 temsirolimus 61 EGFR HER2 61 Vernakalant 61 liposomal doxorubicin 61 metastatic colorectal 61 investigational monoclonal antibody 61 OncoVex 61 Pivotal Study 61 oral salmon calcitonin 61 bevacizumab Avastin 61 small molecule glucokinase 61 HyACT 61 vitro assay 61 Curaxin CBLC# 61 PDX pralatrexate 61 subcutaneously administered 61 Pharmacokinetics PK 61 plasmid DNA vaccine 61 BCR ABL inhibitor 61 GRN# 61 miconazole Lauriad ® 61 Candesartan 61 generation FBPase inhibitor 61 gemcitabine carboplatin 61 Phase 2a Clinical Trial 61 Ophthotech 61 Proxinium TM 61 multi kinase inhibitor 61 diarrhea predominant irritable 61 Aptivus ® 61 Exemestane 61 Pivotal Phase 61 BC# [003] 61 ANG# 61 otelixizumab 61 Angiocept 61 Diamyd R 61 selective orally bioavailable 61 Vaxfectin R formulated 61 proteasome inhibitor bortezomib 61 LUX Lung 61 elacytarabine 61 AMN# [001] 61 methylnaltrexone 61 radiolabeled monoclonal antibody 61 Oncotype DX colon cancer 61 OHR/AVR# 61 VAX# 61 Tanespimycin 61 HCV polymerase 61 nonsmall cell lung cancer 61 inhaled formulation 61 dasatinib Sprycel ® 61 antithrombotic 61 Asentar 61 DDP# 61 DNA intercalator 61 Affibody 61 protease inhibitor PI 61 tenofovir emtricitabine 61 clade B 61 initiate Phase 1b 61 Evoltra ® 61 trastuzumab emtansine T DM1 61 Phase III randomized controlled 61 trodusquemine 61 tumorigenicity 61 CA4P 61 dose intramuscular 61 Phase Ib 61 tramiprosate Alzhemed TM 61 Gastrointestinal Stromal Tumors 61 Japanese Encephalitis Vaccine 61 refractory chronic lymphocytic 61 tumor necrosis 60 anti angiogenic therapy 60 Axiogenesis 60 Crizotinib 60 intranasal delivery 60 Arranon 60 ZACTIMA 60 Cx# [002] 60 ARIKACE ™ 60 Phase 2b clinical trials 60 immunomodulator 60 Omacetaxine 60 SUTENT ® 60 concurrent chemoradiation 60 ProSavin 60 Marqibo TM 60 virotherapy 60 p# biomarker 60 NVA# 60 PGL# 60 ongoing Phase 1b 60 zanolimumab 60 talabostat 60 ATL# [001] 60 Synavive 60 EZN 60 mitogen activated ERK kinase 60 LEUKINE 60 Phase 2a trial 60 fostamatinib 60 Enzastaurin 60 adecatumumab 60 metastatic HRPC 60 non nucleoside HCV 60 INCB# [003] 60 tigecycline 60 bendamustine HCl 60 MYCAMINE 60 Roche Xeloda 60 HuMax HepC 60 oncolytic virus 60 bortezomib Velcade 60 ToGA 60 Zemplar 60 Virulizin ® 60 atrasentan 60 Raltegravir 60 cinacalcet 60 StemEx 60 Alfimeprase 60 daptomycin 60 Alferon N 60 Phase 1b clinical 60 PEP# [003] 60 antiangiogenic agents 60 INS# [001] 60 ruxolitinib 60 Peginterferon alfa 2b 60 Debio 60 Romidepsin 60 MET inhibitor 60 Ofatumumab 60 ularitide 60 ErbB3 60 oncolytic vaccine 60 DXL# 60 Fulvestrant 60 relapsed multiple myeloma 60 chemokine receptor 60 PRO# [003] 60 PXD# 60 delta isoform 60 Tofacitinib 60 Phase #b/#a trial 60 HCV polymerase inhibitors 60 Entecavir 60 Diamyd ® 60 etanercept Enbrel 60 Onrigin 60 PROSTVAC ® 60 ESBA# 60 Antibody Drug Conjugate 60 Altastaph 60 Phase 2a clinical trials 60 FOLOTYN ® 60 immunotherapeutics 60 Nimotuzumab 60 CHAMPION PCI 60 VEGF inhibitors 60 SPD# 60 Bucindolol 60 JAK3 60 metastatic renal cell carcinoma 60 Alemtuzumab 60 seliciclib 60 synthetic retinoid 60 ritonavir boosted protease inhibitor 60 capecitabine Xeloda 60 Therapeutic Vaccine 60 cyclin dependent kinase inhibitor 60 Solazed 60 R#/MEM # 60 brentuximab vedotin SGN 60 histone deacetylase HDAC 60 torezolid phosphate 60 echinocandin 60 Bendamustine 60 oral Janus kinase 60 XL# XL# 60 Enhanze Technology 60 trabedersen 60 CCR5 mAb 60 Phase III Clinical Trials 60 ONTAK 60 thetreatment 60 AS# amonafide L malate 60 Laquinimod 60 lipid nanoparticle 60 Sphingomab 60 tremelimumab 60 ELND# 60 BEMA TM Fentanyl 60 ulimorelin 60 Hycamtin ® 60 Oncaspar 60 MOVIPREP R 60 ARC# [002] 60 Targretin 60 HepaSphere 60 beta 1a 60 CCR5 receptor antagonist 60 xanthine oxidase inhibitor 60 Fidaxomicin 60 Nanobody ® 60 CDP# 60 refractory metastatic colorectal cancer 60 Elitek 60 Doxorubicin 60 RhuDex R 60 Syncria 60 Vidofludimus 60 AEGR 60 galiximab 60 randomized Phase III 60 paclitaxel Taxol ® 60 Phenoptin 60 generation cephalosporin antibiotic 60 preclinically 60 Trabectedin 60 SGLT 60 indibulin 60 VivaGel ™ 60 Natalizumab 60 Eniluracil 60 eprotirome 60 mGluR5 negative 60 Vaprisol 60 Hycamtin 60 phase 2a 60 OncoGel 60 Copegus ribavirin 60 Lu AA# 60 Phase IIb trials 60 renin inhibitors 60 JAK1 60 alemtuzumab Campath 60 HGS ETR1 mapatumumab 60 clobazam 60 S#P# 60 RNAi therapeutic targeting 60 allosteric modulator NAM 60 Anidulafungin 60 hypoxia activated prodrug 60 rPA anthrax vaccine 60 irreversible inhibitor 60 laninamivir 60 desvenlafaxine 60 Actimmune ® 60 PI3K inhibitor 60 5alpha reductase 60 Preclinical studies suggest 60 HuMax 60 mapatumumab 60 Bruton tyrosine kinase 60 AZILECT R 60 Epirubicin 60 Gemzar ® 60 subcutaneous formulation 60 EchoCRT 60 neuronal nicotinic receptor NNR 60 grade cervical intraepithelial 60 recombinant FVIII 60 LHRH agonists 60 Fenretinide 60 adipiplon 60 nilotinib Tasigna 60 SLx 60 Trofile assay 60 crizotinib PF # 60 brivanib 60 aurora kinase 60 Phase 2b Clinical Trial 60 Virulizin R 60 anticancer agent 60 AP# [003] 60 DCCR 60 apaziquone 60 sorafenib tablets 60 recurrent metastatic 60 FLT3 60 Allovectin 7 R 60 mRCC 60 SynCon 60 Plicera 60 LAB CGRP 60 cytostatic 60 Initiates Phase II 60 Diabetic Macular Edema 60 Microplasmin 60 protein kinase inhibitor 60 patented Bioral 60 leading oral taxane 60 non squamous NSCLC 60 Edurant 60 Onalta 60 Rebif ® 60 LX# [003] 60 Herceptin trastuzumab 60 delafloxacin 60 M2 subunit 60 compound AEZS 60 Onco TCS 60 trastuzumab DM1 60 MYDICAR 60 flu mAb 60 BIBW 60 Sudhir Agrawal D.Phil 60 mGluR2 NAM 60 intranasal formulation 60 monoclonal antibody MAb 60 CIMZIA TM 60 posaconazole 60 humanised antibody 60 SCIg 60 relapsing multiple sclerosis 60 PROCHYMAL 60 Thiarabine 60 First Patient Dosed 60 albiglutide 60 Ambrisentan 60 Randomized Phase II 60 humanized monoclonal antibodies 60 tezampanel 60 oral anticancer 60 HBeAg positive 60 novel peptide 60 pegylated liposomal doxorubicin 60 mTOR kinase 60 Mycamine 60 Hexvix 60 modulators SERMs 60 Cervista HPV HR 60 Enkephalin 60 OMNARIS HFA 60 lintuzumab 60 NSCLC tumors 60 investigational pan BCR 60 RhuDex 60 silodosin 60 preclinical efficacy 60 HuCAL antibodies 60 EndoTAGTM 1 60 prostate cancer AIPC 60 Motesanib 60 CCR9 60 ocrelizumab 60 blinded randomized placebo controlled 60 PROSTVAC VF 60 recombinant adeno associated 60 recombinant interferon 60 JAK2 inhibitors 60 Camptosar ® 60 serum biomarker 60 Panitumumab 60 Ridaforolimus 60 Cethromycin 60 Certolizumab pegol 60 Combo Stent 60 alefacept